Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lineage Commitment01:21

Lineage Commitment

3.0K
Commitment is the  process whereby stem cells:
3.0K
Cancer Prevention02:59

Cancer Prevention

6.0K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.0K
Hematopoiesis01:21

Hematopoiesis

5.1K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.1K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

276
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
276
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Direct and indirect regulation of fetal globin transcript by RNA-binding protein IGF2BP1.

Blood·2026
Same author

Parental Perspectives and Experiences with Genetic Testing and Surveillance for Cancer Predisposition in Healthy Young Children.

The Journal of pediatrics·2026
Same author

Beyond neutropenia: Immunological evaluation of patients with Shwachman-Diamond syndrome.

British journal of haematology·2026
Same author

Combining menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia.

Blood advances·2026
Same author

Timing is everything: age-dependent cancer risk in RUNX1-FPD.

Blood advances·2026
Same author

High-resolution single-cell mapping of clonal hematopoiesis and structural variation in aplastic anemia.

Nature genetics·2026
Same journal

The Biology of Malaria Parasite Liver Infection.

Cold Spring Harbor perspectives in medicine·2026
Same journal

The Interaction between Diabetes Mellitus and Tuberculosis: Epidemiology, Screening, and Clinical Management.

Cold Spring Harbor perspectives in medicine·2026
Same journal

New Malaria Prevention Modalities: Long-Acting Interventions Beyond Vaccines.

Cold Spring Harbor perspectives in medicine·2026
Same journal

From Parasite to Pill: Harnessing Biology for Breakthroughs in Antimalarial Drug Discovery.

Cold Spring Harbor perspectives in medicine·2026
Same journal

Malaria Parasite Genomics: Decentralization, Diversification, and Development Goals.

Cold Spring Harbor perspectives in medicine·2026
Same journal

Tuberculosis Infection: Diagnosis and Management.

Cold Spring Harbor perspectives in medicine·2026
See all related articles

Related Experiment Video

Updated: May 28, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.7K

Genetic Predisposition to Hematologic Malignancies.

Kayla V Hamilton1, Akiko Shimamura1,2, Jessica A Pollard3,2

  • 1Division of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

Cold Spring Harbor Perspectives in Medicine
|February 10, 2025
PubMed
Summary
This summary is machine-generated.

Genetic predisposition syndromes (GPS) are increasingly linked to hematologic malignancies (HMs). Early recognition and tailored treatment are crucial for patients with leukemia or lymphoma and potential GPS.

More Related Videos

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
11:06

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

13.0K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.4K

Related Experiment Videos

Last Updated: May 28, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.7K
Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
11:06

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

13.0K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.4K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Hematologic malignancies (HMs) are increasingly associated with underlying genetic predisposition syndromes (GPS).
  • Awareness of diagnostic, physical examination, and family history findings is critical for identifying GPS in patients with HMs.
  • Somatic gene panel testing can reveal mutation profiles suggestive of underlying germline conditions.

Purpose of the Study:

  • To review key features of GPS associated with increased HM risks.
  • To outline diagnostic workup for identifying GPS.
  • To discuss treatment considerations for patients with HMs and GPS.

Main Methods:

  • Literature review of GPS associated with hematologic malignancies.
  • Analysis of diagnostic criteria and family history elements for GPS.
  • Evaluation of treatment implications, including chemotherapy and stem cell transplant, for patients with GPS and HMs.

Main Results:

  • Several GPSs are linked to a higher risk of developing HMs.
  • Specific clinical and genetic findings can indicate an underlying GPS.
  • Identification of GPS impacts HM treatment strategies and monitoring.

Conclusions:

  • Providers should consider GPS in patients diagnosed with leukemia or lymphoma.
  • Recognizing GPS can lead to modified chemotherapy regimens and consideration of hematopoietic stem cell transplant.
  • Understanding GPS is essential for comprehensive HM management and patient care.